T细胞CD62L表达降低及可溶性CD62L水平升高可预测早期慢性期慢性髓系白血病对酪氨酸激酶抑制剂治疗的分子学反应
该前瞻性免疫监测研究伴随ENEST1st临床研究,纳入52例未接受过尼洛替尼治疗的慢性期慢性髓系白血病(CML)患者。诊断时CML患者T细胞CD62L表达降低,与较高Sokal评分、脾脏增大及高白细胞和外周血原始细胞计数相关;尼洛替尼治疗6个月时CD62L表达恢复至健康人水平。CD4+和CD8+ T细胞高CD62L表达及低可溶性CD62L水平与更优分子学反应相关,并在独立验证队列中得到证实。
要点
- 诊断时CML患者T细胞CD62L表达降低,治疗6个月时恢复至健康人水平。
- CD4+和CD8+ T细胞高CD62L表达及低sCD62L水平与更优分子学反应相关。
- CD62L脱落与TACE蛋白酶活性增加相关,尼洛替尼治疗期间TACE活性显著下降。
核心结论
- 诊断时T细胞CD62L脱落及血浆sCD62L水平升高对早期慢性期CML患者酪氨酸激酶抑制剂治疗的分子学反应具有预后影响。
- CD62L降低可能是TACE介导的CD62L剪切增加所致,并可能损害免疫细胞功能。
研究设计与样本
- 前瞻性、综合性流式细胞术免疫监测项目,伴随ENEST1st临床研究开展。
- 研究纳入52例未接受过尼洛替尼治疗的慢性期CML患者,数据在独立验证队列中验证。
主要发现
- 诊断时CML患者T细胞CD62L表达降低,且非T细胞亚群比例异常所致。
- CD62L表达阳性的CD4+和CD8+ T细胞数量低与较高Sokal评分、脾脏增大及高白细胞和外周血原始细胞计数相关。
- 尼洛替尼治疗第6个月时CD62L表达恢复至健康人水平。
- T细胞CD62L丢失程度与可溶性CD62L(sCD62L)升高程度直接相关。
- 诊断时TACE蛋白酶活性增高,尼洛替尼治疗期间显著下降;CD4+和CD8+ T细胞高CD62L表达及低sCD62L水平与更优分子学反应相关,并在独立验证队列中得到证实。
临床怎么用
- 作者认为,诊断时T细胞CD62L脱落及血浆sCD62L水平升高对早期慢性期CML患者酪氨酸激酶抑制剂治疗的分子学反应具有预后影响。
- 作者指出,CD62L降低可能是TACE介导的CD62L剪切增加所致,并可能损害免疫细胞功能。
- 作者提到,更大规模的前瞻性研究正在进行以确认该发现的预后相关性。
局限性
- 原文指出,需要更大规模的前瞻性研究正在进行以确认该发现的预后相关性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Purpose Immunologic surveillance of minimal residual disease in chronic myelogenous leukemia (CML) may be relevant for long-term control or cure of CML. Little is known about immune-modulatory effects of nilotinib in vivo, potentially predicting response to therapy. Patients and Methods A prospective and comprehensive flow cytometry-based immunomonitoring program paralleled the ENEST1st clinical study, investigating 52 nilotinib-naïve patients with chronic-phase CML. Data were verified in independent validation cohorts. Results T cells of patients with CML at diagnosis expressed low l-selectin (CD62L) levels, which was not a result of proportional aberrations of T-cell subsets. Low numbers of CD62L-expressing CD4+ and CD8+ T cells correlated with higher Sokal score, increased spleen size, and high leukocyte and peripheral-blood blast counts. At month 6 during nilotinib therapy, CD62L expression returned to levels of healthy individuals. The level of CD62L loss on T cells directly correlated with the extent of soluble CD62L (sCD62L) elevation. In parallel, the proteolytic activity of tumor necrosis factor α-converting enzyme (TACE; ADAM17, CD156b), the metalloproteinase shedding CD62L, was increased at diagnosis and significantly decreased during nilotinib treatment. High CD62L+ expression on both CD4+ and CD8+ T cells and, vice versa, low sCD62L levels at CML diagnosis were linked to superior molecular responses. These findings were corroborated in independent validation cohorts. Conclusion We demonstrate the prognostic impact of CD62L shedding from T cells and increased sCD62L plasma levels at CML diagnosis on molecular response to tyrosine kinase inhibitor therapy in early chronic-phase CML. Functionally, decreased CD62L may be a consequence of increased TACE-mediated CD62L cleavage and potentially impairs immune-cell function. Larger prospective studies are ongoing to confirm the prognostic relevance of this finding.
引用
- Sopper S, Mustjoki S, White D, et al. Reduced CD62L Expression on T Cells and Increased Soluble CD62L Levels Predict Molecular Response to Tyrosine Kinase Inhibitor Therapy in Early Chronic-Phase Chronic Myelogenous Leukemia. J Clin Oncol. 2016. PMID: 28056193
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。